By
Drug Target Review2025-05-19T01:30:26
Scientists have developed a new drug, SHP1705, that targets hijacked circadian clock proteins used by glioblastoma stem cells to grow and resist treatment.
Already a member? Sign in
By highlighting cutting-edge research and its practical applications, Drug Target Review enables readers to make decisions that accelerate innovation, translate discoveries into therapies, and create tangible benefits for patients worldwide.
By becoming a member you join a connected and collaborative community driving the industry forward. Member benefits include:
2026-11-20T13:00:00Z
2026-11-20T08:00:00Z
Contributor Dr Rahul Gupta, By Drug Target Review
2026-09-17T07:00:00
Contributor Dr Roland Bürli, Dr Francesca Capotosti and Dr Antonella Pirone, By Drug Target Review
2026-07-08T07:58:00
Contributor Dr Nick Lynch, By Dr Raminderpal Singh
2024-01-19T07:40:55
Sponsored by Euretos
2023-07-04T09:00:08
Sponsored by SB Drug Discovery
2023-05-23T11:10:47
Sponsored by NanoTemper Technologies
Site powered by Webvision Cloud